MedPath

The influence of irbesartan on biomarkers of renal function and oxidative stress

Not Applicable
Conditions
hypertension
Registration Number
JPRN-UMIN000013065
Lead Sponsor
ational Defense Medical College
Brief Summary

We could not see specific association betwee urine F-ABP and the administration of irbesartan in the first 10 patients. Then we stopped the trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

(a) patietns exceeding or under the age limit (b) patietns in whom the side effect of irbesartan possibly occure (c) patietns with past heart failure (d) patietns with ejection fraction under 40% (e) patietns with other reasons not appropriate for the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The changes of renal biomarker of liver-type fatty acid binding protein (L-FABP)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath